{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:14:21Z","timestamp":1775794461240,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.drugalcdep.2011.10.018","type":"journal-article","created":{"date-parts":[[2011,11,14]],"date-time":"2011-11-14T06:38:48Z","timestamp":1321252728000},"page":"57-65","source":"Crossref","is-referenced-by-count":45,"title":["Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: Dose\u2013effects and time-course"],"prefix":"10.1016","volume":"123","author":[{"given":"George E.","family":"Bigelow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzie L.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Schmittner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qunming","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Gastfriend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-3565(25)20047-7","article-title":"Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans","volume":"247","author":"Bickel","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0010","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s002130100909","article-title":"Depot naltrexone: long-lasting antagonism of the effects of heroin in humans","volume":"159","author":"Comer","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0020","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2741\/1559","article-title":"The preclinical development of Medisorb\u00ae naltrexone, a once a month long-acting injection, for the treatment of alcohol dependence","volume":"10","author":"Dean","year":"2005","journal-title":"Front. Biosci."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0025","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1530-0277.2006.00052.x","article-title":"Single and multiple dose pharmacokinetics of long-acting naltrexone","volume":"30","author":"Dunbar","year":"2006","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0740-5472(89)90039-1","article-title":"Naltrexone treatment\u2014the problem of patient acceptance","volume":"6","author":"Fram","year":"1989","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0035","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00003495-198835030-00002","article-title":"Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence","volume":"35","author":"Gonzales","year":"1988","journal-title":"Drugs"},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1176\/appi.ps.55.3.221","article-title":"Trends in naltrexone use among members of a large private health plan","volume":"55","author":"Harris","year":"2004","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0376-8716(86)90079-7","article-title":"Comparison of intravenously administered methadone, morphine and heroin","volume":"17","author":"Jasinski","year":"1986","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0055","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/01.ALC.0000139823.30096.52","article-title":"A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence","volume":"28","author":"Johnson","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0060","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0065","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0376-8716(03)00134-0","article-title":"Understanding US addiction physicians\u2019 low rate of naltrexone prescription","volume":"71","author":"Mark","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0070","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1973.01750360022003","article-title":"Naltrexone, an antagonist for the treatment of heroin dependence","volume":"28","author":"Martin","year":"1973","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-3565(25)32374-8","article-title":"Operant analysis of human heroin self-administration and the effects of naltrexone","volume":"216","author":"Mello","year":"1981","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/jcp.0b013e31814ce50d","article-title":"Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment","volume":"27","author":"O\u2019Malley","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0085","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0022-3565(25)22067-5","article-title":"Butorphanol-precipitated withdrawal in opioid dependent human volunteers","volume":"2","author":"Preston","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0090","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1176\/ajp.131.6.646","article-title":"Studies of EN-1639 A (naltrexone): a new narcotic antagonist","volume":"131","author":"Resnick","year":"1974","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0169-409X(97)00048-3","article-title":"Biodegradation and biocompatibility of PLA and PLGA microspheres","volume":"28","author":"Shive","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s002130050199","article-title":"The effects of buprenorphine in buprenorphine-maintained volunteers","volume":"129","author":"Strain","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-006-0509-x","article-title":"Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin","volume":"189","author":"Sullivan","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0110","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0091270005280199","article-title":"Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment","volume":"45","author":"Turncliff","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0115","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0022-3565(25)21159-4","article-title":"Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans","volume":"279","author":"Walsh","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0120","series-title":"Narcotic Antagonists: The Search for Long-Acting Preparations. Research Monograph Series #4. DHEW Publication No. (ADM) 76-296","author":"Willette","year":"1976"},{"key":"10.1016\/j.drugalcdep.2011.10.018_bib0125","series-title":"Narcotic Antagonists: Naltrexone Pharmacochemistry and Sustained-Release Preparations. NIDA Research Monograph #28. DHEW Publication No. (ADM) 81-902","author":"Willette","year":"1981"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871611004698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871611004698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T01:31:42Z","timestamp":1741915902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871611004698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":25,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0376871611004698"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.10.018","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}